Professional Documents
Culture Documents
medoxomilDrugs
azilsartanmedoxomil,aprodrug,ishydrolyzedtoazilsartanintheintestinal
systemduringabsorption.AzilsartanisacarefulAT1subtypeangiotensinII
receptorvillain.
Themedicationmaterialmadeuseofinthemedicationproductformulaisthe
potassium salt of azilsartan medoxomil, also known by the United States
accepted name of azilsartan kamedoxomil and also is chemically called
(5Methyl2oxo1,3dioxol4yl)methyl 2ethoxy1 [2'(5oxo4,5dihydro1,2,4
oxadiazol3yl)biphenyl4yl] methyl 1 Hbenzimidazole7carboxylate
monopotassiumsalt.
Azilsartankamedoxomilisawhitetoalmostwhitepowderwithamolecular
weightof606.62.Itispracticallyinsolubleinwaterandalsoopenlysolublein
methanol.
Edarbiisreadilyavailablefordentaluseastablets.Thetabletcomputershave
a particular smell. Each Edarbi tablet consists of 42.68 or 85.36 mg of
azilsartan kamedoxomil, which is equivalent to containing 40 mg or 80 mg
respectively, of azilsartan medoxomil as well as the adhering to nonactive
components: mannitol, fumaric acid, salt hydroxide, hydroxypropyl cellulose,
croscarmellose sodium, microcrystalline cellulose, and also magnesium
stearate.Manusakttevahasazilsartanmedoxomilfactoryofproduction.
seeminglikeyoumayloseconsciousness;
peinglessornotinanyway;
complication,lossofhunger,vomiting,discomfortinyoursideorlower
back;or
swelling,quickweightgain.
Other
usual
adverse
effects
may
consist
of:
loosenessofthebowels,nausea;
coughing;
kink;
moderatewooziness;or
weakpoint,tired...
Priortotakingazilsartan,tellyourphysicianorpharmacologistifyoudislikeit;
or if you have any other allergic reactions. This item may have nonactive
components,whichcantriggerallergicreactionsorvariousotherissues.Speak
withyourpharmacistforevenmoreinformation.